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Hereditary motor and sensory neuropathies, to which Charcot-Marie-Tooth (CMT) disease belongs, are a common
cause of disability in adulthood. Growing awareness that axonal loss, rather than demyelination per se, is responsible
for the neurological deficit in demyelinating CMT disease has focused research on the mechanisms of early devel-
opment, cell differentiation, and cell-cell interactions in the peripheral nervous system. Autosomal recessive pe-
ripheral neuropathies are relatively rare but are clinically more severe than autosomal dominant forms of CMT,
and understanding their molecular basis may provide a new perspective on these mechanisms. Here we report the
identification of the gene responsible for hereditary motor and sensory neuropathy–Lom (HMSNL). HMSNL shows
features of Schwann-cell dysfunction and a concomitant early axonal involvement, suggesting that impaired axon-
glia interactions play a major role in its pathogenesis. The gene was previously mapped to 8q24.3, where conserved
disease haplotypes suggested genetic homogeneity and a single founder mutation. We have reduced the HMSNL
interval to 200 kb and have characterized it by means of large-scale genomic sequencing. Sequence analysis of two
genes located in the critical region identified the founder HMSNL mutation: a premature-termination codon at
position 148 of the N-myc downstream-regulated gene 1 (NDRG1). NDRG1 is ubiquitously expressed and has
been proposed to play a role in growth arrest and cell differentiation, possibly as a signaling protein shuttling
between the cytoplasm and the nucleus.We have studied expression in peripheral nerve and have detected particularly
high levels in the Schwann cell. Taken together, these findings point to NDRG1 having a role in the peripheral
nervous system, possibly in the Schwann-cell signaling necessary for axonal survival.
Introduction
Hereditary motor and sensory neuropathy–Lom
(HMSNL [MIM 601455]), which is an autosomal re-
cessive form of Charcot-Marie-Tooth disease, occurs
in divergent Romani (Gypsy) groups descended from
a small founder population—the Vlax, or Danubian
Roma. The disorder was first described in affected
families from Bulgaria (Kalaydjieva et al. 1996) and
was subsequently diagnosed in families in Italy (Mer-
lini et al. 1998), Slovenia (Butinar et al. 1999), Ger-
many (Baethmann et al. 1998), Spain (Colomer et al.
2000), France, and Rumania. HMSNL is an early-
onset peripheral neuropathy that progresses to severe
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disability in adulthood. Clinically, it presents with
muscle weakness and wasting, tendon areflexia, skel-
etal and foot deformities, sensory loss affecting all
modalities, and severe reduction in nerve conduction
velocities (Baethmann et al. 1998; Kalaydjieva et al.
1998; Merlini et al. 1998; Butinar et al. 1999). Neural
deafness develops during the second or third decade
of life, with abnormalities in the brain-stem auditory-
evoked potentials suggesting involvement of the entire
tract, including the central auditory pathways (Ka-
laydjieva et al. 1998; Butinar et al. 1999). The neu-
ropathologic observations in HMSNL (Baethmann et
al. 1998; Kalaydjieva et al. 1998; Butinar et al. 1999;
King et al. 1999) include Schwann-cell dysfunction,
which is manifested by hypomyelination and demye-
lination/remyelination, failure of compaction of the
innermost myelin lamellae, and poor hypertrophic re-
sponse (onion-bulb formation) to the demyelination
process. At the same time, axonal involvement is doc-
umented by early, severe, and progressive axonal loss
and by the presence of curvilinear intra-axonal inclu-
sions that are similar to those seen in the dying-back
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type of distal axonopathy in experimental vitamin E
deficiency.
Findings from a number of recent clinical and ex-
perimental studies (Killian et al. 1996; Garcia et al.
1998; Robertson et al. 1999; Sahenk 1999; Sancho et
al. 1999) of the common autosomal dominant demye-
linating forms of Charcot-Marie-Tooth (CMT) disease
have indicated that the neurological deficit in demye-
linating neuropathies is related to axonal loss, rather
than to demyelination per se. The neuropathologic fea-
tures of HMSNL make it impossible to attribute the
primary defect to either Schwann cells or neurons, and
they strongly suggest that impairment of Schwann
cell–axonal interaction is a major component of the
pathogenesis of this disease. The molecular basis of
HMSNL may thus be of relevance to the general un-
derstanding of the pathogenetic mechanisms and causes
of disability in demyelinating neuropathies.
The disease gene was mapped to a 3-cM interval on
8q24.3, where closely related disease haplotypes and
strong linkage-disequilibrium values suggested a single
founder mutation (Kalaydjieva et al. 1996). Similar
polymorphic haplotypes were subsequently identified in
HMSNL chromosomes in affected families across Eu-
rope, supporting the assumption of genetic homogeneity
and founder effect (Chandler et al. 2000). We now re-
port the identification of the HMSNL gene and the
founder mutation causing the disease.
Subjects and Methods
Physical Mapping of the HMSNL Region
A contig of genomic clones spanning the HMSNL in-
terval was assembled by screening of bacterial-artificial-
chromosome (BAC) and PAC libraries for the known
sequence-tagged sites (STSs) in the region and for the
end sequences of clones identified in our previous rounds
of library screening. The screening was performed by
means of PCR amplification (Research Genetics Human
BAC DNA Pools, California Institute of Technology,
B&C libraries, cell line 978K) or filter hybridization
(PAC library #709, RPCI 6, Roswell Park Cancer Insti-
tute; created by Pieter de Jonge and obtained through
the German Human Genome Project Center, Max
Planck Institute). Clone orientation was obtained by STS
content mapping and by halo-FISH (Raap and Wiegant
1994). Nonoverlapping clone ends were used as STSs in
the next round of library walking.
Refined Genetic Mapping
For the identification of new polymorphic micro-
satellites, BAC and PAC contig clones were digested
with frequent cutter restriction endonucleases and
were shotgun cloned into pBluescript. A replica
membrane of the gridded colonies was hybridized
with a cocktail of g[32P]-ATP end-labeled di-/tri-/tet-
ranucleotide repeat sequences, and positive clones
were sequenced. Markers (D8S558, D8S529, D8S378,
and D8S256) available from public databases were
PCR amplified with the use of fluorescently labeled
primers (Research Genetics map pair set), were length-
separated on a 373 XL DNA analyzer (PE Biosys-
tems), and were analyzed using GENOTYPER soft-
ware (PE Biosystems). AFM116yh8 and all newly
identified microsatellites were analyzed through in-
corporation of a[32P]-dCTP into the PCR product dur-
ing amplification. The PCR primers for the newly
identified markers were those described by Chandler
et al. (2000). Vertical-gel electrophoresis, which was
performed in a Hoeffer Pokerface II apparatus, was
followed by autoradiography for 2–12 h. Allele call-
ing was performed manually. Haplotypes were con-
structed manually and were examined for recent and
historical recombinations. The marker positions were
determined by STS content mapping of the contig
clones.
A total of 174 individuals were genotyped for 24
markers in the HMSNL region. Informed consent was
obtained from all participants in the study.
Sequencing
BAC/PAC DNA isolation and purification with the
QIAfilter Plasmid Midi kits were performed according
to the manufacturer’s protocols (Qiagen). End sequenc-
ing was performed using universal primers T7 and SP6.
Sequence analysis of the WISP1 and NDRG1 genes
included all coding regions and 100 bp of flanking
intronic sequences. PCR amplification was performed
using the primers shown in table 1. The PCR products
were purified with Qiagen QIAquick spin columns. Both
strands were sequenced with the same primers used for
PCR amplification.
Sequencing of end clones and PCR products was per-
formed using Big Dye Terminator Cycle Sequencing
Ready Reaction Kit reagents (PE Biosystems). The re-
actions were run on an ABI 377 sequencer (PE Biosys-
tems) and were analyzed using Sequence Navigator soft-
ware, version 1.0.1.
For large-scale genomic sequencing, BAC/PAC DNA
was isolated using the double-acetate method (Birnboim
and Doly 1979). The closed-circle band was sonicated,
and 1.5–2-kb fragments were size-selected by agarose
electrophoresis and were ligated into the SmaI site of
the M13mp18 vector. M13 templates were prepared by
means of the Triton method (Mardis 1994). Shotgun
sequencing was performed using ThermoSequenase
(Amersham) and Big Dye Terminator Cycle Sequencing
Ready Reaction Kit chemistry (PE Biosystems). Data
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Table 1
PCR Primers for Sequencing Analysis of NDRG1 and WISP1
GENE AND EXON
PRIMER
Forward Reverse
NDRG1:
1 GACTGCGAGGGTCTGGGAG CTTACTCCTGGAGTACGC
2 CTTCTTGCCATTGGTCTTG GCATGCCCATAAGTACAAG
3 GATTCAGGTCATAGAAAGG AGAGAAGACGGGATGAGG
4 CACGCGGATGCCATGAAC GCATTTCTGGCTTTTCCAG
5 CTTTGCCACCGAGACACC GAGCAAAGCACCTGAACC
6 CTAATGGCTTCTCTGTGTC GTCAGTCCAGATCAAAGC
7 AGGCTCCCGTCACTCTG GTCTTCCTTCATCTTAAAATG
8 CCTAGTGTTTCAGATTGCTG GAGAGCTCGTAGCTCCAG
9 GGAGTCCAGCAATGCCAC CTGAGCACCACACAATGC
10 GAGTAGTGACCAGCTCAG CAAACTCAGAGCCTGCCTCTTC
11 ACAGGGCCTCTCTCAAGTTG CTGGGTAATGCTCAGTCTC
12 CAGGCCTGGGAGTGGGACAATC GCAGGCAGGGCCACTTCAAC
13 CAAGCCACATCTGCTGAATCC CTTTGCAGCCTCAGATCACC
14 GACACCAGCAGCCTTGCCTG CCTAGGGAATCAGAGTCCTC
15 GGAAACTGGCTCAGACAGG CATGCCCTCCACACACCTAAC
16 GTGGACATGGAGAGGACG GTCTCCACCAGAGCTCACTC
WISP1:
1 CATATCTGGTGCTCCTGATGG GTAGCAGGACCCAGTAGAGAAG
2 GACAGGAATGCAATGGCAG GGTGTATCTCCTGCTGAAC
3 GCATGGTCCACATGGAGCC GGTGGTCAGAGTTCCAGG
4 GTGTGGTGAAAGTGAGGGTTG GCTTGTGAAGTCTAGACATCC
5 GTAAGGTGGAATGCTCCCAC CAGATCAGGGTAACTAAGGC
were collected using ABI 377 automated sequencers and
were assembled with the program PHRAP sequence-
assembly program (University of Washington Genome
Center.
Computational Analysis
The genomic-sequence data were analyzed using the
RUMMAGE-DP program (Genome Sequencing Cen-
tre, Institute of Molecular Biotechnology, Jena, Ger-
many), which combines 125 different programs (ref-
erences available at the Web site of the Genome
Sequencing Centre, Institute of Molecular Biotech-
nology, Jena, Germany), including five programs for
exon prediction; RepeatMasker, for tagging repetitive
sequences; programs for prediction of CpG islands;
and homology searches using BLAST, version 1.4, and
FASTA, version 2.0. Recognition of promoter regions
and transcription-start positions was performed using
both Ghosh/Prestridge (TSSG) and Wigender (TSSW)
motif databases.
Screening for the R148X Mutation
Exon 7 of NDRG1 was PCR amplified as a 176-bp
product, by use of the following primers: 5′-AGGCTC-
CCGTCACTCTG-3′ (forward) and 5′-GTCTCCTTC-
ATCTTAAAATG3′ (reverse). Restriction digests were
performed for 4 h at 65C in a mix containing 1# TaqI
buffer, 10 ml PCR product, and 10 U TaqI (Promega).
The restriction products (lengths 104 bp and 72 bp) were
separated in 4% agarose gels stained with ethidium bro-
mide and were visualized under UV light.
Expression Studies
S.A.G.E. library data were obtained through screening
of our own libraries constructed from peripheral nerve,
glioblastoma, and fetal-brain RNA (Michiels et al. 1999)
and through searching of S.A.G.E. public databases. The
sequence of the NDRG1 S.A.G.E. tag is GGACTTTC-
CT. Expression levels are given as the number of tran-
script tags/106 transcripts in the S.A.G.E. library.
Northern blot analysis was conducted on RNA ex-
tracted, according to standard protocols, from total pe-
ripheral nerve and from cultured nonmyelinating
Schwann cells and hNT2 cells (Sambrook et al. 1989).
Reverse transcriptase–PCR (RT-PCR) of NDRG1 from
RNA derived from the same sources mentioned above
was performed using primers 5′-AACCCACACAGT-
CACCCT-3′ (forward) and 5′-GAAGTACTTGAAGGC-
CTC-3′ (reverse). The 189-bp products were run on a
1% agarose gel in 1# Tris-borate EDTA, were blotted,
and were hybridized with the PCR product obtained
with the same primers.
Analysis of tissue-specific transcripts was performed
by 5′ rapid amplification of cDNA ends (5′-RACE) and
by RT-PCR of two fragments spanning the entire coding
region of NDRG1. 5′-RACE (Boehringer Mannheim 5′/
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3′ RACE kit) was performed on total RNA from human
fetal brain, adult peripheral nerve, and lymphocytes, by
use of the following NDRG1-specific primers: NDRG1-
R1 (5′-ACACAGCGTGACGTGAACAG-3′), for the re-
verse-transcription step); and NDRG1-R2 (5′-CAGAG-
CCATGTAAAGTCTCG-3′) and NDRG1-R3 (5′-ATGT-
CCTGCTCCTGGACATC-3′), for the 5′-RACE reac-
tions. The products were tested on agarose gels and were
sequenced with primer NDRG1-R3. One-step RT-PCR
was performed on the same sources of RNA as was 5′-
RACE, by use of the following two primer pairs:
NDRG1 5′ UTR-F (5′-GAAGCTCGTCAGTTCACC-3′)
and NDRG1 exon 4-R (5′-GTGATCTCCTGCATGT-
CCTC3′), and NDRG1 exon 4-F (5′-GAGGACATGCA-
GGAGATCAC-3′) and NDRG1 exon 15-R (5′-CCAGA-
GGCTGTGCGGGACC-3′).
Radiation-Hybrid Mapping
The chromosomal location of NDRG2 was deter-
mined by radiation-hybrid (RH) mapping. PCR
screening of the GeneBridge RH panel was performed
using primers selected from the unique 3′ UTR se-
quence of KIAA1248, showing no homology to
NDRG1 or NDRG3. The primer sequences were as fol-
lows: NDRG2RH-F2 (5′-CTGGGGCTCCATTCACCA-
AAGC-3′) and NDRG2RH-R2 (5′-AGCCCAGCCCAA-
GCTTAGCTC-3′). The results were submitted to the RH
server of the Whitehead Institute/MIT Center for Ge-
nome Research, for calculation.
Results
Physical and Refined Genetic Mapping
We have assembled a 1-Mb contig of genomic BAC,
PAC, and cosmid clones, with a minimum tiling path
shown in figure 1. The contig spans the entire HMSNL
region, as defined by the recombinations identified in
the initial study (Kalaydjieva et al. 1996). The contig
was anchored to the four known markers in this re-
gion on 8q24, following the order provided by pub-
lic databases (cen-D8S529/D8S378-AFM116yh8-
D8S256-tel). Our subsequent findings have shown the
correct orientation to be as follows: cen-AFM116yh8-
D8S378-D8S529-D8S256-tel. The contig clones were
used for physical mapping of expressed-sequence tags
(ESTs) roughly positioned in this region and for iden-
tification of new polymorphic markers.
Refined genetic mapping included 174 individuals (60
patients and 114 unaffected relatives) from seven Eu-
ropean countries; the individuals were genotyped for 24
polymorphic microsatellites, 19 of which were identified
in our study (Chandler et al. 2000). Ten recombinant
haplotypes, whose distribution differed between disease
chromosomes originating from the diverse Romani
groups, helped to narrow the HMSNL region (fig. 1b).
In five of the seven centromeric recombinations (fig. 1b,
bottom), the breakpoints mapped to the same 90-kb
interval between markers pJ10 and 458b14, thus placing
the centromeric boundary of the region at pJ10. Hap-
lotype analysis of the telomeric recombinants placed the
distal boundary at marker 369CA3 (fig. 1b, right).
Within the pJ10–369CA3 interval, all HMSNL
chromosomes shared an identical haplotype for mark-
ers 458a13-458b57-369a89. This haplotype was not
found in any of the 88 normal chromosomes studied.
Marker 458b14 presented with three different alleles
in the disease chromosomes; however, on the basis of
the conserved flanking haplotypes, this variation was
assumed to result from microsatellite mutations (sim-
ilar to those observed in 339CA2, 189CA17, and, es-
pecially, D8S378; fig. 1b, green boxes).
The critical HMSNL gene interval was thus defined,
on the basis of recombination and homozygosity map-
ping, as being located between newly identified mark-
ers pJ10 and 369CA3. The entire region was con-
tained in three overlapping genomic clones—PAC
709A2498Q2 and BACs 458A3 (GenBank accession
number AF192304) and 369M3 (GenBank accession
number AF186190) (fig. 1). Large-scale sequencing of
these clones identified the final exons of thyroglobulin
in PAC 709A2498Q2 and the full length of two
known genes: the Wnt1-inducible signaling protein 1,
WISP1 (Pennica et al. 1998), in BAC 458A3, and
NDRG1 (aliases RTP, NDR1, DRG1, and CAP43)
(Kokame et al. 1996; Van Belzen et al. 1997; Kur-
distani et al. 1998; Zhou et al. 1998; Xu et al. 1999)
in BACs 458A3 and 369M3 (fig. 1a). WISP1 and
NDRG1 are located tail to tail, in opposite orienta-
tions, and are separated by a small distance of ∼38
kb. The WISP1 gene spans ∼38 kb of genomic DNA,
with the coding regions split into five exons. NDRG1
is spread over 60 kb of genomic DNA and consists
of 16 exons, including an untranslated first exon (fig.
2).
The HMSNL Mutation
The search for the mutation was conducted by se-
quencing of the untranslated and promoter regions, all
exons, and 100 nucleotides of the flanking introns of
WISP1 and NDRG1 in a panel of DNA samples from
patients with HMSNL and unaffected controls from the
same population.
This analysis revealed a total of 13 single-nucleotide
polymorphisms (SNPs) in the two genes (table 2); only
one of the 13 SNPs was in WISP1. The difference is due
to the fact that sequence variation in NDRG1 was in-
vestigated more extensively in individuals of diverse eth-
nic background, whereas WISP1 was analyzed only in
Figure 1 a, Diagram of the BAC, PAC, and cosmid (HCT) clone contig of the HMSNL region. Known genes are represented by arrows pointing in the direction of their transcription. b, Positions
of polymorphic microsatellites used to construct haplotypes on disease chromosomes. The HMSNL critical interval is flanked by markers pJ10 and 369CA3 and contains the WISP1 and NDRG1
genes.
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Figure 2 Scale diagram of the genomic and cDNA organization of NDRG1, with an illustration of the HMSNL mutation. a, Genomic
organization. The NDRG1 gene consists of 16 exons spanning 60 kb of genomic sequence. A CpG island overlaps with the first exon and the
5′ end of intron 1. A potential promoter with a TATA box, a GC box similar to the N-myc binding region of mouse Ndr1, and a TATA-less
enhancer were located 39 bp, 65 bp, and 81 bp upstream, respectively, of the first exon. The 5′ UTR is split between the first two exons. b,
cDNA structure. Translation starts from nucleotide position 123. c, HMSNL mutation: CrT substitution at base 564 results in a stop signal
(TGA) at codon 148 in exon 7 (R148X). All nucleotide positions are given relative to the published sequence (GenBank accession number
D87953).
the Roma. So far, our results have shown that SNPs in
the NDRG1 gene occur with a frequency of 1/423
nucleotides. In patients with HMSNL, the WISP1 gene
sequence was identical to the published wild-type se-
quence.
Analysis of NDRG1 in individuals affected with
HMSNL identified a CrT transition in exon 7, at nu-
cleotide position 564 (according to the numbering of the
reducing agents and tunicamycin-responsive protein
(RTP) sequence [GenBank accession number D87953]).
This substitution results in the replacement of arginine
by a translation-termination signal at codon position
148 (fig. 2). The R148X mutation was found in the
homozygous state in all 60 patients with HMSNL that
were included in the present study.
The CrT substitution abolished a TaqI site, and a
restriction assay was designed as a screening test for the
R148X mutation. In families with HMSNL, the muta-
tion segregated in 100% agreement with the carrier
status predicted by haplotype analysis. Analysis of 69
additional unaffected members of the extended kindred
(the Lom pedigree) in which the disease was first de-
scribed resulted in the detection of 24 carriers.
Screening for the R148X mutation also included 10
Romani families from Rumania who had unspecified
autosomal recessive peripheral neuropathies. The
R148X mutation was found in six of these families, in
whom it cosegregated with the disease phenotype and
occurred in the homozygous state in the affected
patients.
We did not find the R148X mutation among 101 un-
related unaffected control individuals, including 68 non-
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Table 2
SNPs Identified in NDRG1 and WISP1
Gene and SNP Nucleotide Positiona Ethnic Background
NDRG1:
T/G 5′ UTR, nt 15b Afro-American
C/T 5′ UTR, nt 3c Dutch; Roma
C/T Intronic, IVS148 Dutch; Roma
C/T Intronic, IVS25 Afro-American
C/T Intronic, IVS633 Afro-American; Dutch; Roma
A/G Intronic, IVS10  83 Dutch
A/C Intronic, IVS1050 Afro-American; Dutch; Roma
C/T Intronic, IVS117 Roma
C/T Intronic, IVS13147 Afro-American; Dutch; Roma
A/G (293ProrPro) Exon 14, 989c Afro-American
A/C Intronic, IVS14124 Afro-American
A/G 3′ UTR, 1395c Afro-American
WISP1:
C/T (307AsnrAsn) Exon 5, 1009d Roma
a Designated as proposed by Antonarkis et al. (1998), with the positive IVS (intronic)
numbers starting from the G of the donor-site invariant GT and with the negative IVS
numbers starting from the G of the acceptor-site invariant AG. nt = nucleotide position.
b Relative to NDRG1 5′ UTR novel sequence (GenBank accession number
AF230380).
c Relative to mRNA for RTP (GenBank accession number D87953).
d Relative to mRNA WISP1 (GenBank accession number AF100779).
Romani Bulgarians and 33 Roma who originate from
the same groups as do the patients with HMSNL but
who belong to kindreds with other genetic disorders.
The NDRG Family
NDRG1 is a known gene that has previously been
identified in several independent in vitro studies of hu-
man cell lines (Kokame et al. 1996; Van Belzen et al.
1997; Kurdistani et al. 1998; Zhou et al. 1998; Xu et
al. 1999). The encoded protein is highly conserved in
evolution (Kra¨uter-Canham et al. 1997; Shimono et al.
1999; Yamauchi et al. 1999). The genomic organization
of NDRG1, as revealed in the present study (fig. 2), is
also conserved and is closely related to that of the mouse
gene (Shimono et al. 1999).
The results of previous experiments (Van Belzen et al.
1997; Piquemal et al. 1999) have suggested that
NDRG1 is a unique gene; however, a recent study (Van
Belzen et al. 1997; Piquemal et al. 1999) has demon-
strated the existence of an Ndr gene family in the mouse.
Since the existence of homologous genes in humans
could affect the specificity and, hence, the reliability of
expression studies, we have used the novel mouse se-
quences to search the human-genome databases. This
search has confirmed the existence of related human
genes, which we will refer to as NDRG2 and NDRG3,
respectively, for the genes homologous to mouse Ndr2
and Ndr3.
NDRG2 was found to be represented by 147 ESTs
and two cDNA sequences. To determine its chromoso-
mal localization, we have performed RH mapping with
use of the GeneBridge panel. NDRG2 was localized to
chromosome 14q11.2, at 6.72 cR from D14S264, with
LOD score = 15.0.
The NDRG3 gene was represented by 86 ESTs and a
genomic clone from chromosome 20q11.21-q11-23.
This provisional chromosomal localization was con-
firmed by electronic PCR. In the same genomic clone,
this search identified four STSs (three STSs flanking
NDRG3 and one located in its 3′ UTR) that have also
been independently localized to chromosome 20 by
means of RH mapping.
The BLAST comparison showed considerable ho-
mology between the three human NDR genes, with
greater divergence in the terminal parts of the sequences.
At the protein level, the identity (similarity) is 54%
(70%) between NDRG1 and NDRG2, 67% (81%) be-
tween NDRG1 and NDRG3, and 58% (71%) between
NDRG2 and NDRG3. These values are very similar to
the percent homology reported for the members of the
mouse Ndr family (Okuda and Kondoh 1999). Both
mouse Ndr2 and Ndr3 (Okuda and Kondoh 1999) and
human NDRG2 and NDRG3 lack the highly hydro-
philic amino-acid-sequence motif (GTRSRSHTSE) that
is typical of NDRG1 and that is repeated three times at
its C-terminus.
Expression Analysis of NDRG1
The ubiquitous expression of NDRG1 is documented
by 343 entries in the UniGene cluster (GenBank acces-
sion number Hs 75789) and by previous studies (Ko-
kame et al. 1996; Van Belzen et al. 1997; Kurdistani et
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Figure 3 RT-PCR using specific NDRG1 primers in hNT2 cells that are not differentiated (lane 1), hNT2 cells induced to neuronal
differentiation (lane 2), in vitro cultured nonmyelinating Schwann cells (lane 3), total adult peripheral nerve (lane 4), and fetal brain (lane 5).
NDRG1 specificity was confirmed by transfer of the RT-PCR products to a membrane and by back-hybridization with the PCR product.
al. 1998; Zhou et al. 1998; Piquemal et al. 1999; Xu et
al. 1999) using various experimental systems. To date,
no information on the peripheral nervous system has
been published.
To obtain a quantitative comparison of the levels of
NDRG1 expression in different tissues, we have per-
formed S.A.G.E. library screening and database
searches. The following results, presented as the number
of transcript tags/106 transcripts in the S.A.G.E. library,
were obtained: peripheral nerve, 400; colorectal cancer
(HCT116), 213; glioblastoma multiformae libraries,
210 and 99; brain, 146; normal colon and some primary
colon tumors, 81–105; and prostate cancer 139 and 158.
The aforementioned values indicate that NDRG1 is
abundantly expressed in peripheral nerve, where the lev-
els of expression are significantly in excess of those in
the other tissues examined.
Northern blot analysis comparing total adult periph-
eral nerve RNA, cultured nonmyelinating Schwann cells,
and hNT2 cells, which can be induced to neuronal dif-
ferentiation, showed strong signal in total peripheral
nerve and Schwann cells. Expression was lower in un-
differentiated hNT2 cells, and no signal was obtained
in differentiated hNT. In view of the high sequence ho-
mology between the genes of the NDRG family and the
possibility of cross-hybridization, these results were ver-
ified and confirmed by RT-PCR using NDRG1-specific
primers (fig. 3). Our preliminary immunocytochemistry
findings in peripheral nerve point to NDRG1 localiza-
tion in the Schwann-cell cytoplasm, with no evidence of
axonal expression (not shown).
We have used 5′-RACE and RT-PCR to check for the
presence of tissue-specific NDRG1 transcripts in pe-
ripheral nerve, fetal brain, and lymphocytes. The results
of 5′-RACE did not provide evidence of different tran-
scription-start sites: these experiments identified a short
(15-nucleotide) novel additional sequence immediately
upstream of the 5′ UTR of the longest publishedNDRG1
sequence (Kokame et al. 1996), which, however, was
common to all three transcripts. RT-PCR and, subse-
quently, sequencing of the entire coding region of
NDRG1 in peripheral nerve, fetal brain, and lympho-
cytes revealed a single transcript, identical to the pub-
lished cDNA sequence, with no evidence of tissue-spe-
cific alternatively spliced forms.
Discussion
The heterogeneous category of hereditary motor and
sensory neuropathies consists of a large number of clin-
ically and genetically distinct conditions (recently re-
viewed in Keller and Chance [1999] and Schenone and
Mancardi [1999]), including autosomal recessive forms,
some of which have been placed on the human genetic
map (Ben Othmane et al. 1993; Bolino et al. 1996; Ca-
saubon et al. 1996; LeGuern et al. 1996; Bouhouche et
al. 1999). Relative to autosomal dominant CMT disease,
these conditions are rare. However, they are clinically
more severe (Harding and Thomas 1980) and are less
likely to result from mutations in structural myelin pro-
teins; therefore, understanding their genetic basis may
provide insight into hitherto unknown molecular mech-
anisms of peripheral-nervous-system development and
axon-glia interactions. The genetic heterogeneity of au-
tosomal recessive peripheral neuropathies and the lim-
ited number and size of families affected by any single
disorder have presented a major obstacle to molecular
research and gene identification. In the case of HMSNL,
positional cloning was facilitated by the substantial
number of patients identified over a short period of time
after the initial description of the disease as well as by
the history of the disease-causing mutation. HMSNL
occurs in an ethnic group that is marginalized by most
health-care systems; therefore, ascertainment can be pre-
dicted to be limited. The number of affected individuals
in whom a diagnosis has already been made suggests
that the disease is relatively common and may be the
prevalent form of peripheral neuropathy among the
Roma. On the other hand, the origin of the HMSNL
mutation has been estimated to pre-date the arrival of
the proto-Roma in Europe (Kalaydjieva et al. 1996),
indicating that the mutation was present in the ancestral
population before it split into numerous small groups
separated by geographic dispersal, social pressures, and
rules of endogamy. The independent evolution and di-
versification of disease haplotypes in the different Ro-
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mani groups across Europe have provided a powerful
tool for the refined mapping of the HMSNL gene.
The molecular defect shared by all affected individ-
uals was found to be a truncating mutation in NDRG1.
This gene encodes a highly conserved protein with a
high degree of homology to the proteins in other species.
The amino acid similarity to the Drosophila protein is
44%; to sunflower, 48% (Kra¨uter-Canham et al. 1997);
to rat Bdm1, 75% (Yamauchi et al. 1999); and to mouse
Ndr1, 96% (Shimono et al. 1999). These proteins show
no homology to known motifs, except for a putative
phosphopantetheine-binding site (Kokame et al. 1996;
Van Belzen et al. 1997; Piquemal et al. 1999) and a
46% similarity to the ligand-binding domain of the in-
ositol 1,4,5-triphosphate receptor (Kra¨uter-Canham et
al. 1997).
The evolutionary conservation of NDRG1-related
proteins points to an important biological role. The pre-
viously proposed functions of human NDRG1 are
based on studies of non-neural tissues. NDRG1 has
been shown to be repressed in cell transformation (Van
Belzen et al. 1997; Kurdistani et al. 1998) and up-reg-
ulated in growth-arrested differentiating cells (Van Bel-
zen et al. 1997; Kurdistani et al. 1998; Piquemal et al.
1999) and under conditions of cellular stress (Kokame
et al. 1996; Zhou et al. 1998; Xu et al. 1999). Inducing
agents include p53 (Kurdistani et al. 1998), increased
intracellular Ca2 and forskolin (Zhou et al. 1998), re-
tinoic acid, and vitamin D (Piquemal et al. 1999).
NDRG1 expression has been shown to cycle with cell
division (Kurdistani et al. 1998), and studies of the in-
tracellular localization of the protein suggest translo-
cation between the cytoplasm and the nucleus (Van Bel-
zen et al. 1997; Kurdistani et al. 1998; Piquemal et al.
1999). A role as a developmental gene has been doc-
umented for Ndr1, which, in the mouse embryo, is re-
pressed by N-myc and is up-regulated in cells committed
to terminal differentiation (Shimono et al. 1999). The
accumulated data suggest involvement in growth arrest
and cell differentiation during development and in the
maintenance of the differentiated state in the adult, pos-
sibly as a signaling protein shuttling between the cy-
toplasm and the nucleus.
In terms of patterns of expression and proposed gen-
eral functions, NDRG1 clearly resembles PMP22/gas3.
PMP22 is also widely expressed in embryonic and adult
tissues (Patel et al. 1992; Baechner et al. 1995) and is
believed to be involved in growth arrest and cell dif-
ferentiation (Manfioletti et al. 1990; Zoidl et al. 1997).
The highest levels of expression are found in the mye-
linating Schwann cell, where PMP22 is a component of
compact myelin (Snipes et al. 1992). PMP22 is now
known to be responsible for CMT type 1A, hereditary
neuropathy with liability to pressure palsies, and some
forms of Dejerine-Sottas syndrome in humans (Patel et
al. 1992; Timmerman et al. 1992; Valentijn et al. 1992;
Chance et al. 1993; Roa et al. 1993), and for naturally
occurring models of peripheral neuropathy in the mouse
(Suter et al. 1992a, 1992b). A number of studies of
affected humans as well as of natural and transgenic
rodent models have pointed to the complex pathogen-
esis of these disorders where altered myelin stability and
demyelination are only one aspect. The observed sig-
nificant phenotypic changes in both Schwann cells and
axons (Hanemann et al. 1997; Garcia et al. 1998; Sa-
henk 1999; Sancho et al. 1999; Robertson et al. 1999)
have suggested that, in addition to its function as a
myelin protein, PMP22 plays a role in early peripheral-
nervous-system development and differentiation and in
Schwann cell–axonal interactions (reviewed in Naef and
Suter 1998).
Axons and glia in the peripheral nervous system are
involved in a most complex system of communication,
the integrity of which is essential for the differentiation,
survival, and normal function of both types of cells
(Snipes and Suter 1994; Jessen and Mirsky 1998, 1999).
Both the involvement of NDRG1 in these mechanisms
and a possible functional link to PMP22 remain to be
investigated in functional studies as well as through the
identification of NDRG1 mutations in other peripheral
neuropathies. The high levels of NDRG1 expression in
peripheral nerve and, specifically, in the Schwann cell,
together with the characteristics of the HMSNL phe-
notype, point to a possible involvement of NDRG1 in
Schwann-cell differentiation and the signaling necessary
for axonal survival. The role of NDRG1 in growth
arrest and cell differentiation, proposed for other tis-
sues, may thus be conserved in the peripheral nervous
system and may be related to the complex develop-
mental transitions marking the stages of differentiation
of the Schwann-cell lineage and Schwann cell–axonal
interactions (Jessen and Mirsky 1998, 1999). At the
same time, the abundant expression in adult peripheral
nerve and the putative phosphopantetheine-binding
domain present in the NDRG1 protein point to its pos-
sible dual role and additional involvement in the lipid
biosynthetic pathways operating in the myelinating
Schwann cell.
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